To assess the alignment of federal cancer research funding with contemporary measures of disease burden across major cancer types in the US, emphasizing the importance of addressing clinical needs.
Key Findings:
Lung cancers caused 151,401 deaths; pancreatic cancer caused 49,211; breast cancer, 22,606; and prostate cancer, 5,219 deaths, with funding amounts of $2,818 for SCLC, $69,800 for breast cancer, and others specified.
Interpretation:
Cancers with the highest lethality receive lower federal research support, suggesting a misalignment of funding with clinical need and disease burden, which could hinder progress in treatment.
Limitations:
Analysis relied on a single fiscal year of funding data, used estimated rather than observed mortality counts, and lacked granularity regarding funding by research category, potentially affecting the robustness of conclusions.
Conclusion:
A composite framework for federal funding is needed to better align resources with areas of greatest clinical need, integrating incidence with outcome-based measures and addressing funding disparities.
